Sevoflurane
| Clinical data | |
|---|---|
| Trade names | Sevorane, Ultane, others |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy category |
|
| Routes of administration | Inhalation |
| Drug class | Anesthetic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Liver by CYP2E1 |
| Metabolites | Hexafluoroisopropanol |
| Elimination half-life | 15–23 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.171.146 |
| Chemical and physical data | |
| Formula | C4H3F7O |
| Molar mass | 200.056 g·mol−1 |
| 3D model (JSmol) | |
| Density | 1.53 g/cm3 |
| Boiling point | 58.5 °C (137.3 °F) |
| |
| |
| | |
Sevoflurane, sold under the brand name Sevorane, among others, and informally known as sevo, is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether used as an inhalational anaesthetic for induction and maintenance of general anesthesia.
It is on the World Health Organization's List of Essential Medicines.[8]
Medical uses
[edit]Sevoflurane is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia.[9] Whether used alone or in conjunction with intravenous anesthetics such as propofol, it is the most commonly used inhaled anesthetic for induction and maintenance of general anesthesia in modern practice.[10] While desflurane and isoflurane are also effective agents, sevoflurane has gained predominance due to decreased irritation to the airway and having a less pungent odor.[11][12] It is often administered in a mixture of nitrous oxide and oxygen through a sevoflurane-specific calibrated vaporizer attached to an anesthesia machine.[13]
Outside of the operating room, halogenated agents such as sevoflurane are a growing option for sedation in the intensive care unit (ICU).[14] This is due to favorable pharmacokinetics of these agents over intravenous sedation such as bypassing hepatic and renal systems, rapid elimination via exhalation, and having no accumulation effect.[15] However, sedation with inhaled anesthetics such as sevoflurane is not routinely used in North American ICUs currently because of limited experience with the agent among intensivists.[16]
Sevoflurane also has the potential for use in managing patients with status asthmaticus that have failed other medical therapies with improvements in airway resistance and respiratory acidosis.[17]

Contraindications
[edit]Similarly to other volatile anesthetics, sevoflurane should not be administered to any patient with known or suspected genetic susceptibility to malignant hyperthermia. Usage should also be avoided in patients with a known or suspected sensitivity to sevoflurane or other halogenated inhalational agents.[18]
Adverse effects
[edit]Sevoflurane has an excellent safety record,[9] but is under review for potential hepatotoxicity, and may accelerate Alzheimer's.[19] There were rare reports involving adults with symptoms similar to halothane hepatotoxicity.[9] Deeper states of anesthesia with sevoflurane may also lead to generalized muscle spasm.[10]
One of the most prominent adverse effects associated with volatile anesthetics such as sevoflurane is postoperative nausea and vomiting (PONV).[20] Volatile anesthetics were shown to have a dose-dependent effect on PONV, particularly in the first 2-6 hours following surgery.[21] Risk factors for PONV are multifactorial and include prior PONV, motion sickness, female sex, non-smoking status, age < 50 years, longer surgery duration, and use of postoperative opioids.[22] In patients who are at increased risk for PONV, propofol-based total intravenous anesthesia may be preferable and is associated with decreased incidence of PONV.[21]
In patients with pre-existing lung pathology, sevoflurane may precipitate coughing and laryngospasm.[13] Sevoflurane is associated with a lower rate of adverse respiratory events such as coughing, airway irritation, stridor, laryngospasm, and respiratory distress relative to desflurane.[23]
Sevoflurane is an inhaled anesthetic that is often used to induce and maintain anesthesia in children for surgery.[24] During the process of awakening from the medication, it has been associated with a high incidence (>30%) of agitation and delirium in preschool children undergoing minor noninvasive surgery.[24] It is not clear if this can be prevented.[24]
Similarly to other inhaled anesthetics, sevoflurane is associated with a rare but life-threatening complication in susceptible individuals, malignant hyperthermia.[25] This is a hypermetabolic response to volatile anesthetics and can present with hyperthermia, increased CO2 production, increased oxygen consumption, acidosis, hyperkalemia, tachycardia, tachypnea, muscle rigidity, and rhabdomyolysis.[26] Treatment of an acute malignant hyperthermia consists of stopping the triggering agent, administering dantrolene, and providing supportive care.[25]
Sevoflurane has been linked to severe neurological complications and even death in otherwise healthy persons, especially children, with the MT-ND4 11232T>C genetic anomaly. This anomaly originated in Venezuela and is at increased risk for those of Venezuelan ancestry. The genetic anomaly is not known to present with any other symptoms, so those with this mutation will not otherwise know that they are in this group. It is currently unknown if other anesthetics including other volatile anesthetics may by affected.[27][28] This concern prompted the American Society of Anesthesiologists and the Society for Pediatric Anesthesia to issue a joint communication recommending screening for risk, genetic testing through Sanger Sequencing or Rapid Diagnostic Assay for the Sevoflurane Hypersensitivity[29], and avoiding the use of volatile anesthetics in those at risk until more information is available.[30]
Pharmacology
[edit]Pharmacodynamics
[edit]Mechanism of action
[edit]The exact mechanism of the action of general anaesthetics has not been delineated.[31] Sevoflurane acts as a positive allosteric modulator of the GABAA receptor in electrophysiology studies of neurons and recombinant receptors.[32][33][34][35] However, it also acts as an NMDA receptor antagonist,[36] potentiates glycine receptor currents,[35] and inhibits nAChR[37] and 5-HT3 receptor currents.[35][38][39]
Physiological effects
[edit]Sevoflurane is a potent vasodilator. As such, it induces a dose dependent reduction in blood pressure and cardiac output.[13] However, sevoflurane was not associated with an increase in heart rate compared to isoflurane and desflurane.[11] Reduced myocardial oxygen demand and coronary vasodilation is also associated with sevoflurane usage.[40] It reduces the ventilatory response to hypoxia and hypercapnia. Dose-response inhibition of hypoxic pulmonary vasoconstriction is also caused by volatile anesthetics like sevoflurane.[41] The vasodilatory properties of sevoflurane also cause it to increase intracranial pressure and cerebral blood flow. However, it reduces cerebral metabolic rate.[13][42]
Pharmacokinetics
[edit]After desflurane, sevoflurane is the volatile anesthetic with the fastest onset.[43] While its offset may be faster than agents other than desflurane in a few circumstances, its offset is more often similar to that of the much older agent isoflurane. While sevoflurane is only half as soluble as isoflurane in blood, the tissue blood partition coefficients of isoflurane and sevoflurane are quite similar. For example, in the muscle group: isoflurane 2.62 vs. sevoflurane 2.57. In the fat group: isoflurane 52 vs. sevoflurane 50. As a result, the longer the case, the more similar will be the emergence times for sevoflurane and isoflurane.[44][45][46] Sevoflurane has the lowest fat solubility among inhaled anesthetics.[11]
Sevoflurane will degrade into what is most commonly referred to as compound A (fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether) when in contact with CO2 absorbents, and this degradation tends to enhance with decreased fresh gas flow rates, increased temperatures, and increased sevoflurane concentration.[47] Compound A may be correlated with renal damage;[48] while compound A has been shown to be nephrotoxic in animal models, clinically relevant kidney injury has not been demonstrated in humans.[49][50][51]
History
[edit]Sevoflurane was discovered by Ross Terrell alongside Louise Speers in the early 1960s researching at Airco Industrial Gases.[52] Sevoflurane was concurrently synthesized by Richard Wallin.[52] The rights for sevoflurane worldwide were held by AbbVie. It is available as a generic drug.
Global-warming potential
[edit]Sevoflurane is a greenhouse gas. The twenty-year global-warming potential, GWP(20), for sevoflurane is 349, however this is significantly lower than isoflurane or desflurane.[53]
References
[edit]- ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União. Archived from the original on 3 August 2023. Retrieved 16 August 2023.
- ↑ "Ultane- sevoflurane liquid". DailyMed. 18 August 2022. Retrieved 29 June 2024.
- ↑ "Sojourn- sevoflurane liquid". DailyMed. 26 June 2024. Retrieved 29 June 2024.
- ↑ "SevoFlo EPAR". European Medicines Agency. 14 August 2007. Retrieved 29 June 2024.
- ↑ "SevoFlo PI". Union Register of medicinal products. 13 December 2002. Retrieved 29 June 2024.
- ↑ "Sevohale (previously known as Sevocalm) EPAR". European Medicines Agency. 29 July 2016. Retrieved 29 June 2024.
- ↑ "Sevohale PI". Union Register of medicinal products. 24 June 2016. Retrieved 29 June 2024.
- ↑ Organization WH (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- 1 2 3 "Drug Record: Sevoflurane". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012. PMID 31643176. Archived from the original on 15 February 2013.
- 1 2 Wu H, Wang S, Dai FB, Tang CL (March 2025). "Research progress in the clinical application of inhaled anesthetic sevoflurane". Medical Gas Research. 15 (1): 85–92. doi:10.4103/mgr.MEDGASRES-D-23-00003. PMC 11515067. PMID 39436171.
- 1 2 3 Brioni JD, Varughese S, Ahmed R, Bein B (October 2017). "A clinical review of inhalation anesthesia with sevoflurane: from early research to emerging topics". Journal of Anesthesia. 31 (5): 764–778. doi:10.1007/s00540-017-2375-6. PMC 5640726. PMID 28585095.
- ↑ Boonmak P, Boonmak S, Pattanittum P (June 2016). "High initial concentration versus low initial concentration sevoflurane for inhalational induction of anaesthesia". The Cochrane Database of Systematic Reviews. 2016 (6) CD006837. doi:10.1002/14651858.CD006837.pub3. PMC 8676071. PMID 27356171.
- 1 2 3 4 Edgington TL, Muco E, Maani CV (2024). "Sevoflurane". StatPearls. StatPearls Publishing. PMID 30521202.
- ↑ Jabaudon M, Zhai R, Blondonnet R, Bonda WL (October 2022). "Inhaled sedation in the intensive care unit". Anaesthesia, Critical Care & Pain Medicine. 41 (5) 101133. doi:10.1016/j.accpm.2022.101133. PMID 35907598.
- ↑ Feng F, Kang H, Yang Z, Ma L, Chen Y (February 2025). "Safety and effectiveness of inhaled sedation in critically ill patients: a systematic review and meta-analysis". Systematic Reviews. 14 (1) 44. doi:10.1186/s13643-025-02791-6. PMC 11837438. PMID 39972505.
- ↑ Morrison-Nozik A, Wąsowicz M (July 2025). "Volatile anesthetics in the intensive care unit". Anaesthesiology Intensive Therapy. 57 (1): 165–169. doi:10.5114/ait/207183. PMC 12329490. PMID 40696855.
- ↑ Ho GW, Thaarun T, Ee NJ, Boon TC, Ning KZ, Cove ME, et al. (October 2024). "A systematic review on the use of sevoflurane in the management of status asthmaticus in adults". Critical Care. 28 (1) 334. London, England. doi:10.1186/s13054-024-05122-8. PMC 11476279. PMID 39402635.
- ↑ "DailyMed - SEVOFLURANE, (VOLATILE FOR INHALATION)- sevoflurane liquid". dailymed.nlm.nih.gov. Retrieved 29 October 2026.
- ↑ "Anesthetic May Affect Tau Spread in the Brain to Promote Alzheimer's Disease Pathology". Neuroscience News. 16 May 2021. Retrieved 17 May 2021.
- ↑ Khanna SS, Mohammed Abdul MS, Fatima U, Garlapati H, Qayyum MA, Gulia SK (2022). "Role of general anesthetic agents in postoperative nausea and vomiting: A review of literature". National Journal of Maxillofacial Surgery. 13 (2): 190–194. doi:10.4103/njms.NJMS_146_20. PMC 9426712. PMID 36051800.
- 1 2 Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, et al. (August 2020). "Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting". Anesthesia and Analgesia. 131 (2): 411–448. doi:10.1213/ANE.0000000000004833. PMID 32467512.
- ↑ Hu J, Wang Z, Ma B, Wang T, Wang E, Yu W (December 2025). "Clinical practice guidelines for the prevention and management of postoperative nausea and vomiting (2025 edition)". Journal of Anesthesia and Translational Medicine. 4 (4): 286–302. doi:10.1016/j.jatmed.2025.12.002. PMC 13001765. PMID 41929930.
- ↑ Chen WS, Chiang MH, Hung KC, Lin KL, Wang CH, Poon YY, et al. (December 2020). "Adverse respiratory events with sevoflurane compared with desflurane in ambulatory surgery: A systematic review and meta-analysis". European Journal of Anaesthesiology. 37 (12): 1093–1104. doi:10.1097/EJA.0000000000001375. PMC 7752224. PMID 33109925.
- 1 2 3 Costi D, Cyna AM, Ahmed S, Stephens K, Strickland P, Ellwood J, et al. (September 2014). "Effects of sevoflurane versus other general anaesthesia on emergence agitation in children". The Cochrane Database of Systematic Reviews. 2014 (9) CD007084. doi:10.1002/14651858.CD007084.pub2. PMC 10898224. PMID 25212274.
- 1 2 Pinyavat T, Riazi S, Deng J, Slessarev M, Cuthbertson BH, Ibarra Moreno CA, et al. (December 2024). "Malignant Hyperthermia". Critical Care Medicine. 52 (12): 1934–1940. doi:10.1097/CCM.0000000000006401. PMID 39171998.
- ↑ Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K (August 2015). "Malignant hyperthermia: a review". Orphanet Journal of Rare Diseases. 10 (1) 93. doi:10.1186/s13023-015-0310-1. PMC 4524368. PMID 26238698.
- ↑ Lanz-Martínez CA, Echeverría-Villalobos M, Azócar RJ (September 2026). "Anesthetic Management of Two Patients With m. 11232T> C (MT-ND4) Mitochondrial Variant Using Total Intravenous Anesthesia After Sevoflurane Toxicity: A Case Report". A&A Practice. 20 e02288. doi:10.1213/XAA.0000000000002288 (inactive 26 October 2026).
{{cite journal}}: CS1 maint: DOI inactive as of October 2026 (link) - ↑ Levy RJ, Morgan PG (June 2026). "Ancient Mitochondrial Genetic Variant, Modern-day Pandora's Box". Anesthesiology. 144 (6): 1269–1271. doi:10.1097/ALN.0000000000006030. PMC 13273736. PMID 41996624.
- ↑ "Rapid Diagnostic Assay for the Sevoflurane... : Anesthesiology". Ovid. doi:10.1097/ALN.0000000000006399. Retrieved 11 November 2026.
- ↑ "Joint Communication from the American Society of Anesthesiologists and the Society for Pediatric Anesthesia". www.asahq.org. Retrieved 5 November 2026.
- ↑ Perkins B (7 February 2005). "How does anesthesia work?". Scientific American. Scientific American. Retrieved 30 June 2016.
- ↑ Jenkins A, Franks NP, Lieb WR (February 1999). "Effects of temperature and volatile anesthetics on GABA(A) receptors". Anesthesiology. 90 (2): 484–491. doi:10.1097/00000542-199902000-00024. PMID 9952156.
- ↑ Wu J, Harata N, Akaike N (November 1996). "Potentiation by sevoflurane of the gamma-aminobutyric acid-induced chloride current in acutely dissociated CA1 pyramidal neurones from rat hippocampus". British Journal of Pharmacology. 119 (5): 1013–1021. doi:10.1111/j.1476-5381.1996.tb15772.x. PMC 1915958. PMID 8922750.
- ↑ Krasowski MD, Harrison NL (February 2000). "The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations". British Journal of Pharmacology. 129 (4): 731–743. doi:10.1038/sj.bjp.0703087. PMC 1571881. PMID 10683198.
- 1 2 3 Schüttler J, Schwilden H (8 January 2008). Modern Anesthetics. Springer Science & Business Media. pp. 32–. ISBN 978-3-540-74806-9.
- ↑ Brosnan RJ, Thiesen R (June 2012). "Increased NMDA receptor inhibition at an increased Sevoflurane MAC". BMC Anesthesiology. 12 (1) 9. doi:10.1186/1471-2253-12-9. PMC 3439310. PMID 22672766.
- ↑ Van Dort CJ (2008). Regulation of Arousal by Adenosine A(1) and A(2A) Receptors in the Prefrontal Cortex of C57BL/6J Mouse. University of Michigan. pp. 120–. ISBN 978-0-549-99431-2.[permanent dead link]
- ↑ Suzuki T, Koyama H, Sugimoto M, Uchida I, Mashimo T (March 2002). "The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine3 receptors expressed in Xenopus oocytes". Anesthesiology. 96 (3): 699–704. doi:10.1097/00000542-200203000-00028. PMID 11873047.
- ↑ Hang LH, Shao DH, Wang H, Yang JP (2010). "Involvement of 5-hydroxytryptamine type 3 receptors in sevoflurane-induced hypnotic and analgesic effects in mice". Pharmacological Reports. 62 (4): 621–626. doi:10.1016/s1734-1140(10)70319-4. PMID 20885002.
- ↑ Kopańczyk R, Wieruszewski PM, Yin W, Mulvoy WP, Laudanski K, Theodore D, et al. (April 2026). "Volatile Anesthetics: A Comprehensive Review of Pharmacology, Delivery Systems, and Safety Considerations for ICU Practitioners". Critical Care Medicine. 54 (4): 926–938. doi:10.1097/CCM.0000000000007042. PMID 41556744.
- ↑ Licker M, Hagerman A, Jeleff A, Schorer R, Ellenberger C (2021). "The hypoxic pulmonary vasoconstriction: From physiology to clinical application in thoracic surgery". Saudi Journal of Anaesthesia. 15 (3): 250–263. doi:10.4103/sja.sja_1216_20. PMC 8579502. PMID 34764832.
- ↑ Green WB (December 1995). "The ventilatory effects of sevoflurane". Anesthesia and Analgesia. 81 (6 Suppl): S23–S26. doi:10.1097/00000539-199512001-00004. PMID 7486144.
- ↑ Sakai EM, Connolly LA, Klauck JA (December 2005). "Inhalation anesthesiology and volatile liquid anesthetics: focus on isoflurane, desflurane, and sevoflurane". Pharmacotherapy. 25 (12): 1773–1788. doi:10.1592/phco.2005.25.12.1773. PMID 16305297.
- ↑ Maheshwari K, Ahuja S, Mascha EJ, Cummings KC, Chahar P, Elsharkawy H, et al. (February 2020). "Effect of Sevoflurane Versus Isoflurane on Emergence Time and Postanesthesia Care Unit Length of Stay: An Alternating Intervention Trial". Anesthesia and Analgesia. 130 (2): 360–366. doi:10.1213/ANE.0000000000004093. PMID 30882520.
- ↑ Sloan MH, Conard PF, Karsunky PK, Gross JB (March 1996). "Sevoflurane versus isoflurane: induction and recovery characteristics with single-breath inhaled inductions of anesthesia". Anesthesia and Analgesia. 82 (3): 528–532. doi:10.1213/00000539-199603000-00018. PMID 8623956.
- ↑ Smith I, Ding Y, White PF (February 1992). "Comparison of induction, maintenance, and recovery characteristics of sevoflurane-N2O and propofol-sevoflurane-N2O with propofol-isoflurane-N2O anesthesia". Anesthesia and Analgesia. 74 (2): 253–259. doi:10.1213/00000539-199202000-00015. PMID 1731547.
- ↑ Pawson P, Forsyth S (2008). "Anesthetic agents". Small Animal Clinical Pharmacology. pp. 83–112. doi:10.1016/B978-070202858-8.50007-5. ISBN 978-0-7020-2858-8.
- ↑ Eger EI, Koblin DD, Bowland T, Ionescu P, Laster MJ, Fang Z, et al. (January 1997). "Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers". Anesthesia and Analgesia. 84 (1): 160–168. doi:10.1213/00000539-199701000-00029. PMID 8989018.
- ↑ Martin JL, Kandel L, Laster MJ, Kerschmann RL, Eger EI (March 1997). "Studies of the mechanism of nephrotoxicity of compound A in rats". Journal of Anesthesia. 11 (1): 32–37. doi:10.1007/BF02480002. PMID 28921267.
- ↑ Forman SA, Ishizawa Y (2020). "Inhaled Anesthetic Uptake, Distribution, Metabolism, and Toxicity". In Gropper MA, Cohen NH, Eriksson LI, Fleisher LA, Leslie K, Wiener-Kronish JP (eds.). Miller's Anesthesia. Vol. 1 (9th ed.). Philadelphia, PA: Elsevier. pp. 509–539 (531). ISBN 978-0-323-76064-5.
- ↑ Hong I, Bigam KD, McConnell BM, Özelsel TJ, Sondekoppam RV (June 2025). "Sevoflurane and its metabolic byproduct compound A induce nephrotoxicity: a systematic review and meta-analysis of animal studies". Medical Gas Research. 15 (2): 254–265. doi:10.4103/mgr.MEDGASRES-D-24-00080. PMC 11918462. PMID 39829162.
- 1 2 Burns WB, Eger EI (August 2011). "Ross C. Terrell, PhD, an anesthetic pioneer". Anesthesia and Analgesia. 113 (2): 387–389. doi:10.1213/ane.0b013e3182222b8a. PMID 21642612.
- ↑ Ryan SM, Nielsen CJ (July 2010). "Global warming potential of inhaled anesthetics: application to clinical use". Anesthesia and Analgesia. 111 (1). International Anesthesia Research Society: 92–98. doi:10.1213/ane.0b013e3181e058d7. PMID 20519425.
Further reading
[edit]- Patel SS, Goa KL (April 1996). "Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia". Drugs. 51 (4): 658–700. doi:10.2165/00003495-199651040-00009. PMID 8706599.
Haria M, Bryson HM, Goa KL, Patel SS (August 1996). "Erratum". Drugs. 52 (2): 253. doi:10.1007/bf03257493. - Wallin RF, Regan BM, Napoli MD, Stern IJ (November–December 1975). "Sevoflurane: a new inhalational anesthetic agent". Anesthesia and Analgesia. 54 (6): 758–766. doi:10.1213/00000539-197511000-00021. PMID 1239214.
- Drugs developed by AbbVie
- Ethers
- Drugs developed by GSK plc
- GABAA receptor positive allosteric modulators
- General anesthetics
- Glycine receptor agonists
- Greenhouse gases
- Nicotinic antagonists
- NMDA receptor antagonists
- 5-HT3 antagonists
- Fluranes
- Fluoromethyl compounds
- Trifluoromethyl compounds
- Products introduced in 1990
- World Health Organization essential medicines
- Veterinary drugs